Aug 2024
Publication announcement: ADA-308 is a potent antiandrogen in prostate cancer models overcoming enzalutamide treatment resistance
Vancouver Prostate Centre in collaboration with Aranda Pharma has published an article titled “Targeting adenocarcinoma and enzalutamide-resistant prostate cancer using the novel anti-androgen inhibitor ADA-308” in the journal Oncology Reports. The study demonstrates the efficacy of ADA-308 in inhibiting prostate cancer cell growth both in vitro and in vivo and establishes its role as a potent antiandrogen overcoming enzalutamide treatment resistance. Furthermore, the potency of ADA-308 in inhibiting androgen action is underlined by benchmarking against the established antiandrogens enzalutamide and darolutamide used in the treatment of advanced prostate cancer. Access the full publication here: https://doi.org/10.3892/or.2024.8791
Publication announcement: ADA-308 is a potent antiandrogen in prostate cancer models overcoming enzalutamide treatment resistance
Vancouver Prostate Centre in collaboration with Aranda Pharma has published an article titled “Targeting adenocarcinoma and enzalutamide-resistant prostate cancer using the novel anti-androgen inhibitor ADA-308” in the journal Oncology Reports. The study demonstrates the efficacy of ADA-308 in inhibiting prostate cancer cell growth both in vitro and in vivo and establishes its role as a potent antiandrogen overcoming enzalutamide treatment resistance. Furthermore, the potency of ADA-308 in inhibiting androgen action is underlined by benchmarking against the established antiandrogens enzalutamide and darolutamide used in the treatment of advanced prostate cancer. Access the full publication here: https://doi.org/10.3892/or.2024.8791
Oct 2023
Aranda has a new CEO
Aranda Pharma has strengthened the team as Mika Käyhkö has been nominated as the CEO of the company. Aranda’s former CEO Anu Muona will start as a Chief Operating Officer, COO. Mika Käyhkö has over 20 years of leadership experience in international pharmaceutical industry in Europe, working with innovative and generic prescription-, and OTC products. The change will allow Anu to concentrate on managing the company’s R&D programs while Mika will take responsibility on the company’s business development and commercialization activities.
Aranda has a new CEO
Aranda Pharma has strengthened the team as Mika Käyhkö has been nominated as the CEO of the company. Aranda’s former CEO Anu Muona will start as a Chief Operating Officer, COO. Mika Käyhkö has over 20 years of leadership experience in international pharmaceutical industry in Europe, working with innovative and generic prescription-, and OTC products. The change will allow Anu to concentrate on managing the company’s R&D programs while Mika will take responsibility on the company’s business development and commercialization activities.
Apr 2022
Aranda participates in an international Dermatology meeting.
On April 5-7th 2022, Aranda participated in the 3rd Dermatology Drug Development Summit in Frankfurt, Germany.
Aranda participates in an international Dermatology meeting.
On April 5-7th 2022, Aranda participated in the 3rd Dermatology Drug Development Summit in Frankfurt, Germany.
30-Dec-2021, Kuopio, Finland
Aranda Pharma successfully closed its December 2021 fundraising round.
The round was organized via the Invesdor crowdfunding platform. During the round, Aranda hosted two successful investor webinars on 21 Dec 2021, one in Finnish and one in English. A total of 120 people attended the webinars, and 143 new shareholders joined Aranda Pharma.
Aranda Pharma successfully closed its December 2021 fundraising round.
The round was organized via the Invesdor crowdfunding platform. During the round, Aranda hosted two successful investor webinars on 21 Dec 2021, one in Finnish and one in English. A total of 120 people attended the webinars, and 143 new shareholders joined Aranda Pharma.
Feb 2021
Publication Announcement: A novel neuroprotective agent holds promise against neurodegeneration.
The University of Eastern Finland and the University of Helsinki, in collaboration with Aranda Pharma, have published an article titled "An arylthiazyne derivative as a potent inhibitor of lipid peroxidation and ferroptosis, providing neuroprotection in both laboratory and living organisms" in the journal Scientific Reports. The study shows that a condensed benzo[b]thiazine derivative small molecule with an arylthiazine backbone is a potent inhibitor of lipid peroxidation and ferroptosis, providing neuroprotection in vitro and in vivo. Access the full publication here: https://doi.org/10.1038/s41598-021-81741-3.
Publication Announcement: A novel neuroprotective agent holds promise against neurodegeneration.
The University of Eastern Finland and the University of Helsinki, in collaboration with Aranda Pharma, have published an article titled "An arylthiazyne derivative as a potent inhibitor of lipid peroxidation and ferroptosis, providing neuroprotection in both laboratory and living organisms" in the journal Scientific Reports. The study shows that a condensed benzo[b]thiazine derivative small molecule with an arylthiazine backbone is a potent inhibitor of lipid peroxidation and ferroptosis, providing neuroprotection in vitro and in vivo. Access the full publication here: https://doi.org/10.1038/s41598-021-81741-3.
11-Feb-2021, Kuopio, Finland
Aranda Pharma Ltd is Supported by Ely Centre
Aranda Pharma Ltd received a grant from the Centre for Economic Development, Transport and the Environment (ELY Centre). The grant will be used to strengthen and explore international business potential of company’s ADA-308 program.
Aranda Pharma Ltd is Supported by Ely Centre
Aranda Pharma Ltd received a grant from the Centre for Economic Development, Transport and the Environment (ELY Centre). The grant will be used to strengthen and explore international business potential of company’s ADA-308 program.
